**Table 1. Clinical characteristics of patients with non-arteritic anterior ischemic optic neuropathy (NAION) following vaccinations.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Year published** | **Patient demographics** | | | **Vaccine** | **Patient characteristics** | | | | | **Treatment** | **Improvement** |
|  | **Age** | **Sex** | **Type 2 Diabetes** | **Onset after vaccine** | **Laterality** | **Small C/D ratio** | **Visual Field defect** | **MRI** |
| *Mannaseh et al* | 2014 | 68\* | M | + | influenza | 10d | OS | + | inferior altitudinal | normal | n/a | + acuity, not VF |
| 69\* | M | + | influenza | 6d | OD | + | inferior altitudinal | n/a | prednisone | No |
| *Kawasaki et al* | 1998 | 47 | F | - | influenza | 7d OD, 12d OS | OU | + | superior altitudinal OD, inferior altitudinal OS | normal | IV solum edrol and prednisone taper | No |
| 51 | F | - | influenza | 4 weeks | OU | ? | n/a | normal | IV solum edrol | No |
| *Nachbor et al* | 2021 | 64\*\* | F | + | COVID-19 | 6d | OS | + | inferior on CVF | n/a | n/a | No |
| 64\*\* | F | + | COVID-19 | 3d | OS | + | dense constriction | normal | prednisone | + acuity, not VF |

*M=male, F=female, d=days, OD=right eye, OS=left eye, OU=both eyes, VF=visual field, IV=intravenous. \*same patient, 1 year apart. \*\*same patient, 3 weeks apart*